NCT02733445View on ClinicalTrials.gov

Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

CompletedOBSERVATIONAL
Enrollment

2,650

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2016

Conditions
Chronic Myeloid Leukemia (CML)
Interventions
DRUG

dasatinib

DRUG

nilotinib

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY